EUVIMEDObjevte EUVIMED
EUVIMED · CrossrefJournal

The Lancet Haematology

ISSN 2352-3026 · Elsevier BV

Latest articles

  1. Phenotype, treatment, and determinants of prognosis in Erdheim–Chester disease: an international, retrospective, cohort study

    Francesco Pegoraro, Francesco Peyronel, Matthias Papo, Jerome Razanamahery, Francesco Catamerò, Giulia Palazzini, Ilaria Fibbi, Emmanuel Ledoult, Tanguy Le Scornet, Mathilde de Menthon, Etienne Rivière, Achille Aouba, Fleur Cohen-Aubart, Zahir Amoura, Ahmed Idbaih, Xavier Solanich, Polyzois Makras, Vanderson Rocha, Ofer Shpilberg, Oshrat Hershkovitz-Rokah, David L Pottinger, Laura E M Eurelings, Jan A van Laar, Astrid G S van Halteren, Michael Girschikofsky, Matthew J Koster, Nehaal Ahmed, Dongni Yi, Kristian Bowles, Alessandro Tomelleri, Corrado Campochiaro, Kevin O’Brien, Juvianee Estrada-Veras, Pierre Hirsch, Elena Sieni, Gaurav Goyal, Omar Abdel-Wahab, Jean-François Emile, Matthew Collin, Lorenzo Dagna

    Published: 2026-11DOI: 10.1016/s2352-3026(26)00247-4

  2. Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial

    Jeffrey I Zwicker, Aaron P Kithcart, Justin Kaplan, Poulabi Banerjee, Keshini Vyas, Dan Chalothorn, José G Raya, Siyu Li, Laura E Fredenburgh, Mihaela Mocan, Rosen Razboynikov, Lori G Morton, David E Gutstein, Kathryn M Musgrave, Gregory Piazza, Mihaela Mocan, Rosen Razboynikov, Lucian Calmac, Jeffrey I Zwicker, Gregory Piazza, Gerald Soff, Hannah Lee, Ilana Kopolovic, Alejandro Lazo-Langner, Rashid Kazmi, Ariella Tvito, Amichay Meirovitz

    Published: 2026-11DOI: 10.1016/s2352-3026(26)00249-8

  3. Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial

    Zhongli Hu, Zhiping Fan, Min Dai, Hai He, Hua Jin, Zhiqiang Sun, Fen Huang, Na Xu, Qianwei Liu, Yiqing Li, Ying Dong, Ping Zhu, Can Liu, Yunxin Zeng, Jing Sun, Ruijuan Sun, Li Xuan, Qifa Liu

    Published: 2026-11DOI: 10.1016/s2352-3026(26)00250-4

  4. Reducing mortality, improving outcomes, and establishing equity for women with classical haematological disease: a Lancet Haematology Commission

    Luuk J J Scheres, Angela Weyand, Maureen K Baldwin, Jecko Thachil, Maha Othman, Saskia Middeldorp, Maureen Achebe, Rezan Abdul-Kadir, Fionnuala Ní Áinle, Godwin Akaba, Imo Akpan, Homa Ahmadzia, Omolade A Awodu, Marc Blondon, Kochawan Boonyawat, Munira Borhany, Patricia Casais, Briony Cutts, Veronica Flood, Anat Gafter-Gvili, Patricia Homan, Emily Hoppes, Chandani Kharel, Claudia Khayat, Michelle Lavin, Kinga Malinowski, Kristen Matteson, Jackie Maybin, Lauren Merz, Helen Okoye, Alexandra Robledo, Leslie Skeith, Marni Sommer, Tonye Wokoma, Tahira Zafar, Bethany Samuelson Bannow

    Published: 2026-08DOI: 10.1016/s2352-3026(26)00079-7

  5. Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study

    Katelyn P Daniels, Stanley B Pounds, Huiyun Wu, Lei Wang, Thomas B Alexander, Amit Budhraja, Joshua Wolf, Tamara Westover, Paul E Mead, Cyrus M Mehr, Soumyasri Das Gupta, Norman J Lacayo, Hiroto Inaba, Matthew Rees, Ching-Hon Pui, Joseph T Opferman, Jeffery M Klco, Jeffrey E Rubnitz, Seth E Karol

    Published: 2026-08DOI: 10.1016/s2352-3026(26)00136-5

Volumes

2026 · 1552025 · 1802024 · 2062023 · 2112022 · 2032021 · 2052020 · 2142019 · 1332018 · 1262017 · 1412016 · 1202015 · 1252014 · 27

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.